This MedLibrary.org supplementary page on Thrombin-activatable fibrinolysis inhibitor is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
|
carboxypeptidase B2
|
|
| Identifiers | |
| Symbol | CPB2 |
| Entrez | 1361 |
| HUGO | 2300 |
| OMIM | 603101 |
| RefSeq | NM_001872 |
| UniProt | Q96IY4 |
| Other data | |
| Locus | Chr. 13 q14.11 |
Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as plasma carboxypeptidase B2 is a recently described plasma zymogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg92 to a basic carboxypeptidase (TAFIa or activated TAFI) that inhibits fibrinolysis.
TAFI is produced by the liver.
|
|||||||||||
 |
This medical article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 23 February 2008, at 06:23.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Thrombin-activatable fibrinolysis inhibitor".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.